Glaucoma Prediction using Deep Learning

Date : 28/06/2024

Contributers

Nirmit Shekar Karkera (Team Lead)

Rimpi Debnath (Team Member 1)

Dheeraj Pathak (Team Member 2)

Bhumi Singh (Team Member 3)

Sravani Patwari (Team Member 4)

Abstract:

Glaucoma is a major global cause of blindness. As the symptoms of glaucoma appear, when the disease reaches an advanced stage, proper screening of glaucoma in the early stages is challenging. Therefore, regular glaucoma screening is essential and recommended. However, eye screening is currently subjective, time-consuming and labour-intensive and there are insufficient eye specialists available. We present an automatic two-stage glaucoma screening system to reduce the workload of ophthalmologists. This report presents a detailed market segmentation analysis for glaucoma disease prediction, incorporating findings from multiple sources, and explores the business opportunities and technical requirements for developing a prediction system.

Problem Statement:

Glaucoma is a progressive optic neuropathy causing irreversible vision loss if undiagnosed. Early detection remains a challenge due to its asymptomatic nature in initial stages. Glaucoma is a leading cause of blindness worldwide, with no early symptoms, making early detection challenging yet vital. Traditional methods of glaucoma detection involve manual assessment by ophthalmologists, which can be time-consuming and subjective. There is a need for an automated, accurate, and efficient system to assist in the early detection of glaucoma using readily available digital fundus images.

What is Glaucoma:

Glaucoma is a group of eye conditions that damage the optic nerve, crucial for good vision. This damage is often caused by abnormally high pressure in the eye. It is one of the leading causes of blindness for people over the age of 60. Early detection through regular eye exams and proper treatment can prevent or slow down vision loss.

In this Project, we have used VGG16 and ResNet50, which are deep learning models, to detect and classify glaucoma from medical images like retinal scans. These models help in automating the diagnosis process by learning to identify features associated with glaucoma from the training data.



Figure 1. Grading of glaucoma diseases: (**a**) healthy OD; (**b**) Mild Glaucoma; (**c**) Moderate Glaucoma and (**d**) severe glaucoma.

Glaucoma: Causes and Risk Factors

Causes:

1. **Increased Intraocular Pressure (IOP):** Fluid buildup in the eye.
2. **Optic Nerve Damage:** Often due to high eye pressure.
3. **Genetics:** Family history of glaucoma.
4. **Age:** Higher risk after age 60.
5. **Medical Conditions:** Diabetes, heart disease, high blood pressure.
6. **Eye Injuries:** Physical trauma to the eye.
7. **Corticosteroids:** Long-term use of steroid medications.

Risk Factors:

1. **Age:** Higher risk, especially over 60.
2. **Ethnicity:** Higher risk in African Americans, Asians, and Hispanics.
3. **Family History:** Genetic predisposition.
4. **Medical Conditions:** Diabetes, high blood pressure.
5. **Severe Myopia/Hyperopia:** Very nearsighted or farsighted individuals.
6. **Eye Trauma:** Injuries to the eye.
7. **Medications:** Long-term corticosteroid use.

Types of Glaucoma:

1. **Primary Open-Angle Glaucoma (POAG):** Gradual vision loss with no early symptoms.
2. **Angle-Closure Glaucoma:** Sudden pain, headaches, and vision loss due to blocked drainage.
3. **Normal-Tension Glaucoma:** Optic nerve damage with normal eye pressure.
4. **Secondary Glaucoma:** Caused by another condition, like inflammation or trauma.
5. **Congenital Glaucoma:** Present at birth; symptoms include cloudy eyes and light sensitivity.
6. **Pigmentary Glaucoma:** Pigment from the iris blocks fluid drainage, increasing eye pressure.

Symptoms of Glaucoma:

- Early Stages: Often asymptomatic, especially in open-angle glaucoma.
- Progressive Symptoms: Gradual loss of peripheral vision, leading to tunnel vision.
- Acute Angle-Closure Glaucoma Symptoms: Severe eye pain, headache, nausea, vomiting, blurred vision, halos around lights, and redness in the eye.

Prognosis and Management:

Glaucoma is a chronic condition requiring lifelong management. With early detection and proper treatment, significant vision loss can often be prevented. Regular eye exams are essential for monitoring the condition and adjusting treatments as necessary. Advances in technology, particularly AI-driven diagnostic tools, are enhancing early detection and treatment outcomes, providing better management strategies for glaucoma patients. This ongoing innovation and vigilant management can significantly improve the quality of life for individuals affected by glaucoma.

Assessment:

Customer Need Assessment:

Glaucoma, often termed the "silent thief of sight," affects millions of people worldwide, with the World Health Organization estimating it as the second leading cause of blindness globally. The prevalence of glaucoma varies by region, with higher incidences reported in Africa and Asia compared to Europe and North America. Early detection is crucial as it can prevent the progression of the disease and preserve vision. Patients at risk, including those over 40, individuals with a family history of glaucoma, and people with conditions like diabetes, are the primary target market. These patients need affordable, accessible, and accurate screening tools to manage their eye health proactively. Ophthalmologists, clinics, and hospitals are also critical customers, as they require reliable diagnostic tools to serve their patients better. Additionally, the ageing population and increasing incidence of diabetes are escalating the demand for efficient glaucoma screening, emphasising the necessity for innovation in this field.

Patients and healthcare providers need reliable, non-invasive, and early diagnostic tools to manage glaucoma effectively. Automated systems can reduce human error and improve early detection rates.

Market Need Assessment:

The market for glaucoma detection is expanding rapidly due to the increasing ageing population and heightened awareness of the importance of eye health. The global glaucoma treatment market was valued at approximately USD 5.6 billion in 2020 and is projected to grow at a CAGR of 5.3% from 2021 to 2028. This growth is driven by advancements in medical technology, increased healthcare spending, and supportive government initiatives aimed at early disease detection. Despite this growth, current glaucoma detection methods face significant challenges, such as high costs, limited accessibility in rural or underdeveloped areas, and the need for specialised equipment and trained personnel. These challenges create a substantial need for innovative solutions that can bridge the gap between demand and supply. Furthermore, the rise in telemedicine and mobile health applications offers new avenues for deploying portable glaucoma detection tools, catering to both developed and emerging markets where traditional healthcare infrastructure may be lacking.

There is a growing demand for advanced diagnostic tools in ophthalmology, driven by the increasing prevalence of glaucoma and the ageing population. The market is segmented by device type, end-user, and region.

Business Need Assessment:

From a business perspective, developing a portable and cost-effective glaucoma detection tool using machine learning (ML) and deep learning (DL) models presents a lucrative opportunity. The healthcare sector is increasingly adopting AI-driven solutions due to their potential to improve diagnostic accuracy and efficiency. Regulatory bodies like the FDA in the U.S. and the EMA in Europe have also started to streamline the approval process for AI-based medical devices, making it easier to bring innovative products to market. Companies venturing into this space must navigate regulatory requirements, ensure data privacy and security, and establish robust partnerships with healthcare providers. Success in this market hinges on demonstrating the clinical efficacy of the product, achieving regulatory approval, and effectively marketing the product to healthcare professionals and end-users. Additionally, a clear understanding of reimbursement policies and insurance coverages, as well as developing a strong post-market surveillance plan, is crucial for maintaining long-term market presence and customer trust.

Target Specifications:

- Accuracy: High diagnostic accuracy, preferably over 90%.
- Usability: User-friendly interface for both patients and healthcare providers.
- Integration: Compatibility with existing ophthalmic equipment.
- Cost: Affordable for widespread adoption.

Target Specifications and Characterization for Glaucoma Diagnosis:

Target specifications for glaucoma diagnosis involve precise evaluation of optic nerve health, intraocular pressure (IOP), and visual field integrity. Key methods include assessing optic nerve appearance, measuring IOP using tonometry, and detecting peripheral vision loss through visual field tests.

Characterization relies on clinical criteria to define glaucoma based on these factors, supplemented by advanced imaging and AI-driven analysis for enhanced accuracy. Effective management includes regular monitoring of optic nerve and visual field changes, personalised treatment plans to control IOP, and integrating portable AI-enabled devices for accessible and efficient screening. Regulatory compliance and integration into healthcare systems are crucial for implementing these advancements and improving diagnostic precision and patient outcomes globally.

External searches:

These are some of the sources that we have gone through which shows how effectively AI is being used in glaucoma prediction.

https://glaucoma.org/research

https://www.nei.nih.gov/research/clinical-trials/landmark-clinical-vision-and-eye-research/glaucoma-research

https://www.delveinsight.com/report-store/glaucoma-market

https://glaucomatoday.com/articles/2022-mar-apr/glaucoma-in-india-personal-and-broader-impacts

https://www.nature.com/articles/s41598-023-44473-0

https://www.eurchembull.com/uploads/paper/550992e85f7f08e1f0bb838debba9206.pdf
https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-024-02518-y

https://link.springer.com/article/10.1007/s11277-020-08029-z#citeas

https://www.sciencedirect.com/science/article/pii/S2666521221000144

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611813/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611813/

https://www.jait.us/uploadfile/2023/JAIT-V14N6-1186.pdf

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611813/

Benchmarking:

Traditional glaucoma detection methods rely on techniques such as tonometry, ophthalmoscopy, and visual field testing. These methods have been effective in diagnosing and monitoring glaucoma but often require specialised equipment and trained personnel. Tonometry measures intraocular pressure, ophthalmoscopy examines the optic nerve, and visual field tests assess peripheral vision loss. While these methods are well-established and clinically validated, they may have limitations in early detection and accessibility, especially in underserved regions.

AI-driven solutions represent a significant advancement in glaucoma detection. Machine learning and deep learning algorithms can analyse retinal images with high accuracy, detecting subtle changes indicative of early-stage glaucoma. AI models process data rapidly, offering quick results that enable timely intervention to prevent vision loss. Portable AI-enabled devices provide flexibility and affordability, potentially reducing healthcare costs. Despite regulatory and implementation challenges, AI's continuous learning capability improves diagnostic precision over time, potentially surpassing traditional methods in sensitivity and specificity.

Traditional Methods:

- Relies on tonometry, ophthalmoscopy, and visual field testing.
- Requires specialised equipment and trained personnel.
- Established and clinically validated.
- May have limitations in early detection and accessibility.

AI-Driven Solutions:

- Utilises machine learning and deep learning algorithms.
- Analyses retinal images with high accuracy.
- Provides rapid results for timely intervention.
- Portable devices enhance flexibility and affordability.
- Challenges include regulatory approval and initial implementation costs.
- Continuous learning improves diagnostic precision over time.

Applicable Constraints:

- **Regulatory Approvals**: Compliance with FDA and other international regulations.
- **Data Privacy**: Adherence to HIPAA and other data protection laws.
- **Cost**: Balancing high development costs with affordable pricing.

Business Opportunity:

Creating a business centred on glaucoma presents diverse opportunities in healthcare innovation and service delivery. Developing AI-driven diagnostic solutions tailored for early detection through retinal imaging analysis can revolutionise how glaucoma is diagnosed, offering accuracy and efficiency. Additionally, establishing teleophthalmology services enables remote consultations and monitoring, enhancing accessibility to specialised care, especially in underserved areas. Investing in research and development for novel medications, therapies, and surgical techniques aimed at managing intraocular pressure and preventing vision loss represents another key area.

Educational initiatives and digital health platforms can play a crucial role in raising awareness about glaucoma prevention and treatment options, empowering patients and healthcare providers alike. Expanding into emerging markets with growing healthcare needs and forming strategic partnerships with healthcare providers, research institutions, and government bodies can foster global reach and impact.

Navigating regulatory landscapes and providing compliance consulting services for new diagnostic and treatment technologies are critical for ensuring adherence to industry standards and accelerating market entry. By focusing on these opportunities, businesses can not only drive innovation in glaucoma care but also make significant strides in improving patient outcomes and quality of life worldwide.

Concept Generation:

Concept generation for glaucoma disease involves leveraging AI for accurate early detection through retinal imaging, establishing telemedicine platforms for remote care and monitoring, and developing personalised treatments based on genetic and clinical data. Initiatives include patient education through digital platforms, integrating glaucoma management tools into healthcare systems, and fostering global partnerships for outreach and innovation. Regulatory expertise ensures compliance and facilitates market entry for novel diagnostics and therapies, aiming to enhance glaucoma detection, treatment, and patient outcomes globally.

During concept generation, we are considering these approaches:

- **Technological Integration**: Exploring AI algorithms to analyse retinal images or biomarkers for early glaucoma detection with high accuracy.
- **Device Design**: Designing a portable device integrating AI models for real-time analysis, ensuring ease of use and accessibility in diverse healthcare environments.
- **Data Utilisation**: Leveraging big data analytics to enhance diagnostic capabilities, potentially integrating with electronic health records (EHRs) for comprehensive patient management.
- **Cost-Effectiveness**: Investigating cost-effective software development processes and scalable business models to ensure affordability and competitiveness.
- **Regulatory Compliance**: Understanding regulatory requirements for medical devices and planning for certification and approval processes.

Concept Development:

Concept development involves refining the selected idea into a detailed plan for the glaucoma detection tool. This phase builds upon the concepts generated during ideation, focusing on creating a tangible product or service that meets market needs and technical requirements. Key activities during concept development include:

- **Detailed Product Specification**: Defining technical specifications such as imaging resolution, algorithm complexity, and connectivity options (e.g., Wi-Fi or Bluetooth).
- **Prototype Development**: Building initial prototypes to validate technical feasibility and performance metrics, conducting iterative testing and refinement.
- **User Experience Design**: Designing intuitive user interfaces (UI) and user experience (UX) features to ensure ease of use for healthcare professionals and patients.
- **Business Model Formulation**: Developing a sustainable business model, including pricing strategies, revenue streams (e.g., device sales, subscription services), and potential partnerships.
- **Regulatory Strategy**: Planning for regulatory approval, including compliance with FDA or other relevant authorities, and addressing data privacy and security concerns.
- **Market Validation**: Conducting market research and obtaining feedback from stakeholders, including potential users and investors, to validate market demand and refine the product roadmap.

Concept development transforms ideas into actionable plans, laying the foundation for successful implementation and commercialization of the AI-driven glaucoma detection tool. This phase ensures alignment with market needs, technological capabilities, and regulatory requirements, setting the stage for the next steps in product development and deployment.

Final Product Prototype:

GlaucoDetect AI represents a breakthrough in glaucoma detection technology, integrating advanced machine learning models to analyse retinal images with exceptional accuracy. Designed for precision and accessibility, GlaucoDetect AI features a compact and user-friendly portable device suitable for use in various healthcare settings.

Key components of GlaucoDetect AI include a robust Flask API backend hosting the AI model, facilitating seamless communication with healthcare systems for efficient data processing and integration. Complementing this it also features a robust frontend application developed using JavaScript frameworks like React.js for web applications and a Java-based Android app for mobile use, these applications empowers healthcare professionals with real-time access to diagnostic data and patient information, enhancing clinical decision-making and patient management.

With a focus on early detection and proactive treatment planning, GlaucoDetect AI aims to prevent irreversible vision loss associated with glaucoma. It offers scalable deployment options and adheres to rigorous medical device regulations (e.g., FDA, CE), ensuring safety and efficacy in clinical practice. By addressing global healthcare challenges through innovation and technology, GlaucoDetect AI is poised to improve diagnostic accuracy, patient outcomes, and healthcare delivery efficiency in ophthalmology.

Monetization:-

Glaucoma involves leveraging innovative diagnostic tools like GlaucoDetect AI for early detection, offering subscription services for ongoing updates and telemedicine consultations, and providing data analytics insights. Educational programs for healthcare professionals, strategic partnerships for distribution, and participation in clinical research further enhance revenue opportunities. These strategies not only improve patient care and outcomes but also sustainably grow business in the healthcare sector.

- **Components**: High-resolution OCT, AI-based analysis software, user interface.
- **Features**: Real-time image analysis, automated reports, cloud storage for data.

How It Works:

1. Capture retinal images using OCT.
2. Analyse images using AI algorithms.
3. Generate diagnostic reports highlighting potential glaucomatous changes.

Data Sources:

- Retinal image datasets from Kaggle.

- https://www.kaggle.com/datasets/sshikamaru/glaucoma-detection/data
- Patient records for model training and validation.

Algorithms, Frameworks, Software Needed:

- **Algorithms**: Convolutional Neural Networks (e.g., ResNet50, VGG-16)
- **Frameworks**: TensorFlow, PyTorch
- **Software**: Custom diagnostic software for image analysis and reporting.

Team Required to Develop:

- **AI Specialists**: Develop and train diagnostic algorithms.
- **Ophthalmologists**: Provide medical expertise and validate diagnostic criteria.
- **Software Engineers**: Develop the user interface and integrate AI with imaging devices.
- **Regulatory Experts**: Ensure compliance with healthcare regulations.

Code Implementation/Validation on Small Scale:

In this project, we used pandas to load and manipulate data, extracting labels for training. Additionally, we employed NumPy and the Python Imaging Library (PIL) to handle image data. By loading and visualising images with PIL and Matplotlib, we prepared them for further processing. To enhance our model training, we used TensorFlow's ImageDataGenerator for data augmentation and VGG16's preprocess_input function for image preprocessing. These tools collectively facilitated efficient data preparation, processing, visualisation, and augmentation for our analysis and model training.

```
train_label = pd.read_csv('/content/drive/MyDrive/glaucoma (1).csv')
y_train = train_label['Glaucoma']
train_label.head()
```

	Filename	ExpCDR	Eye	Set	Glaucoma
0	001.jpg	0.7097	OD	A	0
1	002.jpg	0.6953	OS	A	0
2	003.jpg	0.9629	OS	A	0
3	004.jpg	0.7246	OD	A	0
4	005.jpg	0.6138	OS	A	0

```
import matplotlib.pyplot as plt
fig, ax0 = plt.subplots()
ax0.imshow(image)
ax0.axis('off')
ax0.set_title('image')
# ax1.imshow(pixels)
# ax1.axis('off')
plt.show()
```

Further, we utilised Keras to build a deep learning model for image classification. We integrated a pretrained VGG16 & ResNet50 model for feature extraction, freezing its layers to prevent retraining. By adding custom fully connected layers on top, we enhanced the model's ability to classify images into specified classes. Dropout regularisation was employed to mitigate overfitting. The model was compiled with softmax activation for multiclass classification. These configurations enabled efficient training and optimization of the model for our classification task.

Then, we used Keras' ImageDataGenerator to preprocess and augment image data for training and testing. For both generators, we applied preprocessing functions using preprocess_input from the respective pretrained model (likely VGG16 & ResNet50). Augmentation techniques such as rotation, horizontal and vertical flips, and shifts were implemented to enhance the dataset's diversity and robustness. These generators were configured to feed batches of preprocessed images into our deep learning model, facilitating effective training and evaluation.

```
train_datagen = ImageDataGenerator(preprocessing_function = preprocess_input,
                                   rotation_range = 90,
                                   horizontal_flip = True,
                                   vertical_flip = True,
                                   width_shift_range=0.2,
                                   height_shift_range=0.2,
                                   zoom_range=0.1,)

test_datagen = ImageDataGenerator(preprocessing_function = preprocess_input,
                                  rotation_range = 90,
                                  horizontal_flip = True,
                                  vertical_flip = False)

train_generator = train_datagen.flow_from_directory(TRAIN_DIR,
                                                    target_size = (HEIGHT, WIDTH),
                                                    batch_size = BATCH_SIZE)

test_generator = test_datagen.flow_from_directory(TEST_DIR,
                                                  target_size = (HEIGHT, WIDTH),
                                                  batch_size = BATCH_SIZE)

Found 520 images belonging to 2 classes.
Found 130 images belonging to 2 classes.
```

Then, We developed a custom deep learning model using a VGG16 base without pretrained weights and excluded its classification layers. The model included fully connected layers with 1024, 512, and 256 units, applying dropout regularisation (0.5) for binary classification using binary cross entropy loss. Training utilised the Adam optimizer with checkpoint callbacks to save weights based on validation accuracy. Data generators were used for preprocessing and augmenting images from specified directories (TRAIN_DIR and TEST_DIR), ensuring compatibility with the model's input dimensions. Overall, these setups facilitated effective model training and evaluation.Overall, these setups facilitated effective model training and evaluation.

```
1024
512
256
{'Glaucoma_Negative': 0, 'Glaucoma_Positive': 1}
Model: "model"
_________________________________________________________________
 Layer (type)                Output Shape              Param #
=================================================================
 input_1 (InputLayer)        [(None, 300, 300, 3)]     0

 block1_conv1 (Conv2D)       (None, 300, 300, 64)      1792

 block1_conv2 (Conv2D)       (None, 300, 300, 64)      36928

 block1_pool (MaxPooling2D)  (None, 150, 150, 64)      0
```

```
dense_1 (Dense)             (None, 512)              524800

dropout_1 (Dropout)         (None, 512)              0

dense_2 (Dense)             (None, 256)              131328

dropout_2 (Dropout)         (None, 256)              0

dense_3 (Dense)             (None, 2)                514

=================================================================
Total params: 57839682 (220.64 MB)
Trainable params: 43124994 (164.51 MB)
Non-trainable params: 14714688 (56.13 MB)
_________________________________________________________________
```

Using a custom VGG16-based model, we made predictions for a binary classification task and evaluated its performance using a confusion matrix. This allowed us to assess the model's accuracy & we did with an Accuracy Score of 0.7384.

```
Epoch 1/20
 65/150 [===========>.................] - ETA: 2:36 - loss: 3.4979 - accuracy: 0.6385WARNING:tensorflow:Your input ran out of data;
150/150 [==============================] - 169s 1s/step - loss: 3.4979 - accuracy: 0.6385 - val_loss: 0.7375 - val_accuracy: 0.7385
```

```
[ ]  from sklearn.metrics import accuracy_score, confusion_matrix
     import numpy as np
```

```
Y_pred = vgg16_model.predict(test_generator)
y_pred = np.argmax(Y_pred, axis=1)
print('Confusion Matrix')
cf_matrix = confusion_matrix(test_generator.classes, y_pred)
print(confusion_matrix(test_generator.classes, y_pred))
```

```
17/17 [==============================] - 8s 495ms/step
Confusion Matrix
[[96  0]
 [34  0]]
```

```
[ ]  Y_pred = vgg16_model.predict(test_generator)
     y_pred = np.argmax(Y_pred, axis=1)
```

```
17/17 [==============================] - 13s 732ms/step
```

```
[ ]  print("ACCURACY SCORE  :",accuracy_score(test_generator.classes,y_pred))
```

```
ACCURACY SCORE  : 0.7384615384615385
```

Now we are doing classification using ResNet50 :

We fine-tuned a ResNet50 model for binary classification by adding custom layers and applying dropout regularisation. Training utilised Adam optimizer with a low learning rate, and checkpoints were set to save model weights based on validation accuracy. TensorBoard was used for monitoring training metrics.

```
Downloading data from https://storage.googleapis.com/tensorflow/keras-applications/resnet/resnet50_
94765736/94765736 [==============================] - 0s 0us/step
1024
512
256
{'Glaucoma_Negative': 0, 'Glaucoma_Positive': 1}
Model: "model_1"
__________________________________________________________________________________________________
 Layer (type)                Output Shape                 Param #   Connected to
==================================================================================================
 input_2 (InputLayer)        [(None, 300, 300, 3)]        0         []

 conv1_pad (ZeroPadding2D)   (None, 306, 306, 3)          0         ['input_2[0][0]']

 conv1_conv (Conv2D)         (None, 150, 150, 64)         9472      ['conv1_pad[0][0]']

 conv1_bn (BatchNormalizati  (None, 150, 150, 64)         256       ['conv1_conv[0][0]']
 on)

 conv1_relu (Activation)     (None, 150, 150, 64)         0         ['conv1_bn[0][0]']
```

```
 flatten_1 (Flatten)         (None, 204800)               0         ['conv5_block3_out[0][0]']

 dense_4 (Dense)             (None, 1024)                 2097162   ['flatten_1[0][0]']
                                                          24

 dropout_3 (Dropout)         (None, 1024)                 0         ['dense_4[0][0]']

 dense_5 (Dense)             (None, 512)                  524800    ['dropout_3[0][0]']

 dropout_4 (Dropout)         (None, 512)                  0         ['dense_5[0][0]']

 dense_6 (Dense)             (None, 256)                  131328    ['dropout_4[0][0]']

 dropout_5 (Dropout)         (None, 256)                  0         ['dense_6[0][0]']

 dense_7 (Dense)             (None, 2)                    514       ['dropout_5[0][0]']

==================================================================================================
Total params: 233960578 (892.49 MB)
Trainable params: 210372866 (802.51 MB)
Non-trainable params: 23587712 (89.98 MB)
__________________________________________________________________________________________________
```

The model's training and validation accuracy were extracted from the training history. The final accuracy values were printed, along with the corresponding losses. The validation accuracy was converted to a percentage for clarity and our model gives Accuracy Score of 0.7385.

```
Epoch 1/20
 65/150 [===========>.................] - ETA: 37s - loss: 1.3146 - accuracy: 0.6885WARNING:tensorflow:Your input ran out of data; in
150/150 [==============================] - 48s 269ms/step - loss: 1.3146 - accuracy: 0.6885 - val_loss: 0.7433 - val_accuracy: 0.7308
```

We generated predictions using our fine-tuned ResNet50 model for a binary classification task and computed a confusion matrix to evaluate its performance. The matrix provides insights into how well the model correctly classified instances across the specified classes.

Performance ResNet50

```
training_accuracy = history.history['accuracy']
validation_accuracy = history.history['val_accuracy']
training_loss = history.history['loss']
validation_loss = history.history['val_loss']

print(f"Training Accuracy: {training_accuracy[-1]:.4f}")
print(f"Validation Accuracy: {validation_accuracy[-1]:.4f}")
print(f"Training Loss: {training_loss[-1]:.4f}")
print(f"Validation Loss: {validation_loss[-1]:.4f}")

accuracy = (validation_accuracy[-1] * 100)
print(f"\n\nModel Accuracy: {accuracy:.2f}%")
```

```
Training Accuracy: 0.6885
Validation Accuracy: 0.7308
Training Loss: 1.3146
Validation Loss: 0.7433


Model Accuracy: 73.08%
```

```
Y_pred = resnet50_model.predict(test_generator)
y_pred = np.argmax(Y_pred, axis=1)
print('Confusion Matrix')
cf_matrix = confusion_matrix(test_generator.classes, y_pred)
print(confusion_matrix(test_generator.classes, y_pred))
```

```
17/17 [==============================] - 9s 440ms/step
Confusion Matrix
[[81 15]
 [30  4]]
```

GitHub Link:

https://github.com/Nirmitkarkera01/Glaucoma-Predection-Using-Deep-Learning.git

CONCLUSION:

In conclusion, leveraging advancements in artificial intelligence, particularly through models like VGG16 and ResNet50, presents a compelling business opportunity in the field of glaucoma detection and management. By integrating these state-of-the-art deep learning models into diagnostic tools such as GlaucoDetect AI, businesses can enhance early detection capabilities with unprecedented accuracy. This not only improves patient outcomes by enabling timely intervention but also addresses global healthcare challenges related to accessibility and affordability of advanced diagnostic technologies.

Furthermore, the incorporation of technologies like Keras' ImageDataGenerator for data preprocessing and augmentation underscores the robustness and effectiveness of these AI-driven solutions. Augmenting image datasets with techniques such as rotation, flips, and shifts enhances dataset diversity, thereby improving model generalisation and performance.

As businesses explore the commercialization of glaucoma detection technologies, considerations around regulatory compliance, market scalability, and integration with existing healthcare infrastructure are crucial. Collaborations with healthcare providers and institutions, coupled with ongoing research and development, will drive innovation and expand market reach.

In conclusion, the convergence of AI technologies like VGG16 and ResNet50 with business models focused on glaucoma detection not only promises significant advancements in healthcare but also represents a sustainable avenue for growth and impact in improving global eye health outcomes.

BUSINESS MODEL

Developing a robust business model for glaucoma disease involves strategically integrating innovative solutions and services to address healthcare needs effectively. Central to this model is the creation of value through advanced diagnostic tools like GlaucoDetect AI, designed for early detection and monitoring of glaucoma. This entails targeting healthcare providers, clinics, and hospitals as primary customers, offering them reliable and accessible diagnostic solutions.

Revenue generation hinges on multiple streams such as direct sales of diagnostic devices, subscription-based telemedicine services, and consultancy fees for data analytics and strategic guidance. Establishing efficient distribution channels, including partnerships with medical distributors and online platforms, ensures broad market reach while navigating regulatory requirements.

Key activities include continuous research and development to enhance product features and diagnostic accuracy, supported by clinical validation and collaborations with healthcare professionals. Managing costs effectively, including investment in technology and compliance measures, is crucial for sustainable growth.

Strategic partnerships with healthcare providers and research institutions bolster market presence and facilitate technological integration. This approach not only aims to capture value through competitive pricing and recurring revenue models but also emphasises ethical practices and patient-centred care, ensuring long-term viability and impact in glaucoma management.

Market Analysis:

The early detection and management of glaucoma in rural areas present a significant opportunity for innovation. Currently, most hospitals and clinics in these regions lack advanced diagnostic tools for glaucoma, relying heavily on traditional, manual methods. With the rapid advancement of data science, AI, and machine learning, the healthcare industry is poised for transformation. However, there are very few service providers offering AI-driven solutions for glaucoma detection in rural healthcare settings. The market is at a nascent stage where both healthcare providers and patients may not be fully aware of the potential benefits of AI in glaucoma management. This gap presents a substantial opportunity for early entrants to establish a strong market presence and demonstrate the critical need for such technology in improving patient outcomes.

Market Drivers and Trends:

1. **Rising Prevalence of Glaucoma**: An increasing number of glaucoma cases worldwide is driving the demand for diagnostic tools.
2. **Increasing Elderly Population**: The growing elderly demographic, which is more susceptible to glaucoma, boosts market demand.
3. **Advancements in Diagnostics Technology**: Innovations in diagnostic devices and instruments enhance the accuracy and efficiency of glaucoma detection.
4. **Growing Investments in Healthcare**: Increased funding and investment in healthcare infrastructure support market growth.
5. **Preventive Care Focus**: Rising awareness and emphasis on early detection and management of glaucoma drive market expansion.

Operating Plan:

Our operation hinges on assembling a proficient team of AI and ML engineers with substantial knowledge of the healthcare industry, particularly in ophthalmology. The product development team will consist of AI specialists, ophthalmologists, software engineers, and regulatory experts. AI specialists create and refine diagnostic algorithms, ophthalmologists validate medical insights, software engineers design user interfaces and integrate AI with imaging devices, and regulatory experts ensure compliance with healthcare regulations. This collaboration ensures the system's accuracy, usability, and regulatory adherence, essential for successful deployment in clinical settings.

The development timeline for the glaucoma prediction system will be established through detailed discussions with the client to ensure alignment on deadlines and project milestones. This collaborative approach will enable us to prioritize and accelerate certain phases of development as necessary.

Given that rural hospitals may be unfamiliar with AI-based diagnostic tools, we will initially offer our services at a reduced price to encourage adoption. After successfully implementing our system with the first client and evaluating its performance, we will reassess our pricing strategy. Our pricing will be tiered based on the size and type of hospital, ensuring affordability and scalability.

Marketing Plan:

To market our glaucoma prediction system, we will begin by compiling a comprehensive list of hospitals and clinics in rural areas. For each facility, we will assess the likelihood of them adopting new technology. This assessment will guide our outreach strategy, allowing us to target the most promising prospects effectively.

We will approach hospital administrators and representatives, presenting a clear and compelling case for our product. This will include detailed explanations of how our AI-driven system can enhance diagnostic accuracy, streamline patient management, and ultimately improve clinical outcomes. Demonstrating the system’s potential to increase efficiency and reduce the burden on ophthalmologists will be key to gaining buy-in.

Word-of-mouth referrals and positive testimonials from early adopters will play a crucial role in building trust and generating demand. By proving the value of our technology through initial implementations, we expect to create a ripple effect, encouraging more rural hospitals to adopt our solution.

Financial equation:



Figure 2: Glaucoma treatment market size from 2023-2033 [USD- Billion]

Market Size(in USD Billion) = 14488.9518−14.5155×Year+0.00363636×Year2

Key Points:

- **Year**: This is the independent variable, representing the calendar year.
- **Market Size**: This is the dependent variable, representing the market size in billions of USD.

Explanation:

- The **constant term** (14488.9518) sets the base level of the market size.
- The **linear term** (-14.5155 × Year) suggests that the market size decreases annually by this amount, but this is offset by the quadratic term.
- The **quadratic term** (0.00363636 × $Year^2$) indicates that the market size follows a parabolic trend, with the decrease slowing down over time and potentially turning into growth.

In summary, the market size for glaucoma treatment initially decreases but the rate of decrease slows down, potentially leading to growth in the market size towards the end of the period.

Conclusion:

Market basket analysis is a data mining technique that reveals associations between products purchased together by customers. It helps businesses understand consumer behaviour, optimise marketing strategies like cross-selling and promotions, and improve operational efficiency. By analysing transactional data, businesses can identify patterns, increase sales, and enhance customer satisfaction through targeted insights and strategic actions. This approach is particularly beneficial for small businesses looking to leverage data to boost sales and foster growth.